Viking Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Corporate Update – marketscreener.com
Posted: October 29, 2020 at 8:59 pm
SAN DIEGO - Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2020, and provided an update on its clinical pipeline and other corporate developments.
Highlights from the Quarter Ended September 30, 2020: 'The third quarter at Viking was highlighted by continued pipeline progress, with enrollment now ongoing in two important clinical programs,' stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. 'The Phase 2b VOYAGE study of our lead NASH program, VK2809, continues and we anticipate completion of enrollment in the first half of 2021. In addition, at the EASL conference in August, we presented new data from the prior 12-week study of VK2809, demonstrating consistent liver fat reductions across high risk subgroups, as well as durable efficacy maintained four weeks after completion of dosing. With respect to our VK0214 program for X-linked adrenoleukodystrophy, we are excited to have moved this important program into the clinic, with the announcement of a Phase 1 SAD/MAD study in healthy subjects. Pending successful completion, in 2021 we plan to initiate a Phase 1b study in patients with X-ALD. Both of these clinical trials continue to advance despite disruptions resulting from the COVID-19 pandemic. Finally, to support both of these programs, we continue to judiciously manage our balance sheet and ended the quarter with $255 million in cash.'
Pipeline and Corporate Highlights
Phase 2b VOYAGE study of VK2809 in biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis continues. VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH. The company's ongoing Phase 2b VOYAGE trial is a randomized, double-blind, placebo-controlled, multicenter study designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3. The study is targeting enrollment of approximately 340 patients across five treatment arms: 1.0 mg daily; 2.5 mg daily; 5.0 mg every other day; 10.0 mg every other day and placebo. The primary endpoint of the study will evaluate the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction (MRI-PDFF) from baseline to Week 12 in subjects treated with VK2809, as compared to placebo. Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of dosing.
Despite disruption from the coronavirus pandemic, the majority of our U.S. clinical sites are open for enrollment. The company plans to expand the number of clinical sites over the next few months to include over 80 U.S. clinical sites and more than 90 sites globally. The company anticipates completion of enrollment in the first half of 2021.
New data from VK2809 Phase 2 trial highlighted during podium presentation at EASL 2020. New data from the company's prior 12-week Phase 2 study evaluating VK2809 in the treatment of non-alcoholic fatty liver disease and hypercholesterolemia were highlighted during an oral presentation at the 2020 EASL meeting. The newly reported data demonstrated that patients treated with VK2809 experienced highly durable, statistically significant reductions in liver fat content that were maintained at Week 16, four weeks after completion of dosing in the 12-week study. The results showed that among VK2809-treated patients, the median reduction in liver fat content was 45.4% at Week 16, compared to an 18.7% reduction for placebo (p=0.0053). Additionally, at Week 16, 70.4% of all VK2809-treated patients maintained a response, defined as experiencing 30% relative reduction from baseline in liver fat content (p=0.0083). Of note, 100% of patients receiving 5 mg daily doses of VK2809 maintained a response at Week 16.
Additionally, new analyses of Week 12 study results demonstrated significant reductions in liver fat content among patients receiving VK2809 as compared to placebo regardless of the presence of common risk factors for NASH, including baseline levels of alanine aminotransferase (ALT) above the upper limit of normal (ALT > xULN), body mass index (BMI) 30, hypertension and Hispanic ethnicity.
The overall results from this study, including these new durability data, as well as the observed consistent efficacy across high risk subgroups, provide strong rationale for further development of VK2809 in the setting of NASH, and may indicate opportunities for multiple dosing strategies, including chronic, intermittent, or the potential cycling of treatment modalities.
Initiated Phase 1 trial evaluating VK0214 for the treatment of X-ALD. VK0214 is a novel, orally available thyroid receptor beta agonist being evaluated as a potential treatment for X-linked adrenoleukodystrophy (X-ALD), a devastating disease for which there is currently no therapeutic treatment. To date, findings from in vitro and in vivo studies have demonstrated that administration of VK0214 results in a significant reduction of very long chain fatty acids in both plasma and tissue, key biomarkers of disease, suggesting a potential therapeutic benefit.
During the third quarter, the company advanced this program into clinical development by initiating a Phase 1 first-in-human trial. The Phase 1 trial is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy subjects. The primary objectives of the study include evaluation of the safety, tolerability, and pharmacokinetics of single and multiple oral doses of VK0214, as well as the identification of VK0214 doses for further clinical development in the setting of X-ALD. Upon successful completion of the SAD/MAD study, the company plans in 2021 to advance this program into a proof-of-concept trial in patients with X-ALD.
Balance sheet remains strong with over $255 million in cash. Viking completed the third quarter of 2020 with $255.3 million in cash, cash equivalents and short-term investments.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
Forward-Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones, including the company's expected timing for the potential initiation and completion of clinical studies in X-ALD for VK0214 and plans for completion of the company's VOYAGE Phase 2b study, as well as the company's goals and plans regarding VK0214, VK2809 and their respective prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2809 and VK0214; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; risks related to the COVID-19 pandemic and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including Viking's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law.
Contact:
Michael Morneau
Tel: 858-704-4660
Email: mmorneau@vikingtherapeutics.com
Excerpt from:
Viking Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Corporate Update - marketscreener.com
- The 5 Best Nutrient-Rich Foods to Improve Thyroid Function - The Beet - January 19th, 2021
- Medicare and thyroid tests: Coverage, options, therapies, and costs - Medical News Today - January 19th, 2021
- High court grants leave to appeal to UK gender identity service - The Guardian - January 19th, 2021
- Data Show More Women Are Freezing Their Eggs During the Pandemic, Defying Doctors Expectations - TIME - January 19th, 2021
- NHS wins right to appeal cruel High Court ruling that restricts healthcare for trans kids - PinkNews - January 19th, 2021
- Six Trans People Talk About Their Pandemic Bodies - BuzzFeed News - January 19th, 2021
- Follicle Stimulating Hormone Test Kit Market Overview, Trend Analysis, Competitive Landscape, Forecast to 2027 | Easydiagnosis, Wondfo, Daan - Splash... - January 19th, 2021
- Parler reappears on web, still not in app stores - Yahoo News UK - January 19th, 2021
- Trump Administration begins moving out of the White House - Yahoo News UK - January 19th, 2021
- The ProLon Fasting Mimicking Diet: Whats the Skinny? - Prestige Online - January 19th, 2021
- UofG PART OF INTERNATIONAL RESEARCH NETWORK STUDYING CAUSES OF HYPERTENSION - India Education Diary - January 19th, 2021
- Trans Women are Taking Hormones Without Medical Supervision in Uganda - VICE UK - January 14th, 2021
- Multitasking Meds Combat HIV, Along With Alzheimer's and Diabetes - HivPlusMag.com - January 14th, 2021
- Racism and Bias Make Infertility Treatment Even More Inaccessible to Couples of Color - Well+Good - January 14th, 2021
- Functional Connectivity in Certain Brain Regions May Be Associated with Hormone Therapy Outcomes in Transgender Patients - Psychiatry Advisor - January 12th, 2021
- The best prenatal vitamins for women and how to take them to boost your fertility - Insider - INSIDER - January 12th, 2021
- Why I'm Sharing Everything About My Experience As a Pregnant Dad - VICE - January 12th, 2021
- Forum Health, LLC adds Meridian Health Center to its growing community of Integrative and Functional Medicine practitioners - Yahoo Finance - January 9th, 2021
- Current Approaches and Unmet Needs in the Treatment of Metastatic Breast Cancer - AJMC.com Managed Markets Network - January 9th, 2021
- Forum Health, LLC adds Healing Arts Center to its growing community of Integrative and Functional Medicine practitioners - Iosco County News Herald - January 9th, 2021
- Nonprofit providing unusual form of therapy for those on front lines puppy cams - The Denver Channel - January 9th, 2021
- UPDATED: Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic - Endpoints News - January 9th, 2021
- Experts treat insomnia, anxiety caused by COVID-19 - Spartan Newsroom - Spartan Newsroom - January 9th, 2021
- 5 Ways Gut Health Affects Your Sex Life and How Probiotics Can Help - Healthline - January 9th, 2021
- Is 90% of Serotonin Found in the Gut? - Snopes.com - January 9th, 2021
- Telemedicine Is Revolutionizing Abortion Health Carein Ways Likely To Persist Long Past COVID - Ms. Magazine - January 9th, 2021
- Next-Generation Cytotoxic Therapy Moves Forward in mCRPC - OncLive - January 9th, 2021
- Transgender Health Program at the University of Utah - SLUG Magazine - January 9th, 2021
- Premature Menopause Market 2021-28 healthcare leads to shooting revenues with Novo Nordisk A/S, Pfizer, Allergan, Eli Lily and Company, Emcure... - January 9th, 2021
- The Men's Health Partners and Greenville Men's Clinic Merger Changes the Way Men's Healthcare is done in South Carolina - PR Web - December 30th, 2020
- My fertility treatment failed three times in 2020 and I discovered how to live with uncertainty - The Guardian - December 30th, 2020
- The 11 Healthiest Lunches to Have, According to Dietitians | Eat This Not That - Eat This, Not That - December 30th, 2020
- The Most Dangerous Soda Habits You Need to Kick, Say Doctors - Eat This, Not That - December 30th, 2020
- Type 2 diabetes: Blurred vision and floaters in the eyes are signs of high blood sugar - Express - December 30th, 2020
- 7 New Acne-Treating Ingredients Alternative Acne Treatments - Allure Magazine - December 30th, 2020
- Winter got you down? It could be Seasonal Affective Disorder - PostBulletin.com - December 30th, 2020
- Thyroid Stimulating Hormone Test Kit Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026 | Innodx,... - December 30th, 2020
- Lasofoxifene Emerges as Understanding of ESR1 Mutations Expands in ER+/HER2- Breast Cancer - OncLive - December 30th, 2020
- Tips for mental health resilience in the time of COVID - Plattsburgh Press Republican - December 30th, 2020
- Do you have symptoms of low testosterone? - KTAR.com - December 17th, 2020
- Why COVID-19 Might Lead to Erectile Dysfunction in Some People, According to Doctors - Prevention.com - December 17th, 2020
- Las Colinas Cancer Center is Recognized as a Leader in Clinical Research and Personalized Cancer Care - Irving Weekly - December 17th, 2020
- How to strengthen your immune system this winter - USA TODAY - December 17th, 2020
- You Might Not Absorb as Much Vitamin D as You ThinkHere's How to Maximize the Process - msnNOW - December 17th, 2020
- Coping with social isolation | News | standard.net - Standard-Examiner - December 17th, 2020
- Breast cancer screening and COVID-19 | Feeling Fit - yoursun.com - December 17th, 2020
- A Time to Man-Up: Supporting the Menopausal Women in Your Life - The Good Men Project - December 17th, 2020
- Heres the Deal With Your Junk Food Cravings - Health Essentials from Cleveland Clinic - December 16th, 2020
- Puberty blockers and consent to treatment: an analysis of the High Court's ruling - Communitycare.co.uk - December 16th, 2020
- New Global Pooled Analysis Supports Clinical Utility of Circulating Tumor Cell Count for Early Monitoring of Metastatic Breast Cancer - PRNewswire - December 16th, 2020
- This One Thing Can Predict Your Risk of Disease, Says Science - Yahoo Lifestyle - December 16th, 2020
- Period Poops: Why They Happen and What You Can Do About Them - LIVESTRONG.COM - December 16th, 2020
- Dozens of bird and mammal species have been saved from extinction since 1993 - Massive Science - December 16th, 2020
- Uniklinik RWTH Aachen is the First Hospital to Implement Sphingotec's Innovative Biomarkers in Clinical Routine with the Aim of Making Intensive Care... - December 16th, 2020
- How to Reduce the Winter Blues With Plant-Based Food - LIVEKINDLY - December 16th, 2020
- What Is Gambling Addiction and Problem Gambling? - GamblingNews.com - December 16th, 2020
- Why I was right to blow the whistle on the Tavistock Clinic over puberty blockers - Telegraph.co.uk - December 9th, 2020
- The Role of Race, Ethnicity, and Cancer in the Time of COVID-19 - AJMC.com Managed Markets Network - December 9th, 2020
- Northfield school district employee terminated for unauthorized treatment of infant; Rice County law-enforcement breaks theft ring; Big Woods State... - December 9th, 2020
- How Keke Palmer found out the truth about her PCOS - Nicki Swift - December 9th, 2020
- Gynecological cancers and the global COVID-19 pandemic - DocWire News - December 9th, 2020
- Here's how much sleep your kids need to stay healthy - INFORUM - December 9th, 2020
- Here Are The Types Of Birth Control Available In Malaysia And How Much They Cost - SAYS - December 9th, 2020
- Why some people never gain weight | Health Gulf News - Gulf News - December 9th, 2020
- Hudson Hormone Replacement Therapy and Anti-Aging in ... - December 7th, 2020
- LoveJoy Home | LOVEJOY Hormone Clinic - December 7th, 2020
- UK court rules against clinic in puberty blocking drugs case - ABC News - December 7th, 2020
- Parathyroid Hormone Testing in Veterans with Kidney Stones and Hypercalcemia - DocWire News - December 7th, 2020
- Noise For Now Connects The Indie Scene To Support Women's Health Care - UPROXX - December 7th, 2020
- Medical history from the year you were born - Bryan-College Station Eagle - December 7th, 2020
- Dar Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis -... - December 7th, 2020
- Epidemiology Forecast on Acromegaly and Gigantism to 2029 - - GlobeNewswire - November 24th, 2020
- IVF: "I was absolutely heartbroken the first time it didn't work" - RTE.ie - November 24th, 2020
- Earlier menopause, fewer pregnancies linked to early onset of progressive MS - West Central Tribune - November 23rd, 2020
- Healthy Living: Are you sick and tired of feeling sick and tired? - Leinster Leader - November 23rd, 2020
- Jan Morris, Celebrated Writer of Place and History, Is Dead at 94 - The New York Times - November 23rd, 2020
- How to Know If the Abortion Pill Worked and What to Do Next - Healthline - November 23rd, 2020
- For one breast cancer survivor in Gaza Strip, a journey of hardship and hope - UNFPA News - November 23rd, 2020
- 7 Causes of Excessive Gas That Aren't Food - LIVESTRONG.COM - November 23rd, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 19th, 2020